CHOICE: CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy FRESH-PEF67-en CHOICE: CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy CHOICE FRESH-PEF67-en 67 FRESH-PEF67 LILLY FRANCE Epidemiology France Portal (PEF) LILLY FRANCE null Type-2 diabetes insulin exenatide undesirable effects HbA1c quality of life Endocrinology Healthcare system determinants: Use of care Healthcare system determinants The primary objective of this study is to estimate the time spent on initial treatment regime before significant treatment change for patients with type 2 diabetes initiating therapy with either insulin or exenatide for the first time. null France Germany Sweden Denmark Belgium Greece Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Adults 18 years and older, - Type-2 diabetes patients who have never received insulin or exenatide and who are initiating a treatment via exenatide or insulin therapy, within the normal routine course of care. Clinical data Participant-reported health data Biological data Health event/morbidity Health care consumption and services Quality of life/health perception Other Through independent healthcare practitioners Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Interview with the participant (including clinical) Observational Study Observational Study 2388 (1114 exenatide, 1274 insulin) Unknown Restricted access Access on specific project only